Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

Genetic Testing Offers New Hope for Children with Brain Cancer

More than half of pediatric cancer patients have genetic faults that could affect their diagnosis or be targeted by drugs.

In the past 30 years, childhood deaths from cancer have declined by 50 percent overall, but those from pediatric brain cancer have only decreased by 30 percent.

Researchers at the Dana-Farber Cancer Institute and Boston Children’s Hospital think precision medicine, the idea that treatments can be customized to individuals based on their genetics and other health information, could help improve those rates.

Investigators conducted genetic testing on 203 patient tumor samples and found that 56 percent of them harbored genetic abnormalities that could either help doctors diagnose or treat the brain tumor with drugs that are already available or those being studied in clinical trials.

The findings of their study, published in the journal Neuro-Oncology last week, also highlight key genetic differences in pediatric brain tumors compared to adult ones, suggesting that brain tumors in children and adults need to be treated differently.

Currently, such cancer genomic tests aren’t routine. They’re not covered by many health insurance plans or common outside research hospitals.

Genomic testing of pediatric brain tumor samples may help guide diagnosis and treatment.

“The reason why we’re doing this for kids with brain tumors is that we’re not winning with standard treatments,” says co-lead study author Pratiti Bandopadhayay, a pediatric neuro-oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Pediatric brain tumors are the leading cause of childhood deaths from cancer. Surgery, radiation, and chemotherapy have been the standard treatments.

For decades, every child with the same tumor type received the same treatment, says Bandopadhayay. “We’re learning that when you look at these tumors under the microscope, even if they look the same, they might have different genetic drivers.”

While more cancer therapies that target specific genetic differences in tumors are coming onto the market, there are no FDA-approved targeted cancer drugs specifically for pediatric brain tumors.

One of the most common genetic mutations found among the 203 tumor samples was in the BRAF gene, which, when mutated, has the potential to cause normal cells to become cancerous ones. Two drugs for melanoma that target BRAF have been approved by the U.S. Food and Drug Administration. One of those, dabrafenib, is currently being tested in clinical trials for some types of pediatric brain tumors.

Targeted therapies are likely to be most effective when they're matched to specific abnormalities within tumor cells. But Ann Kingston, director of research and scientific policy at the National Brain Tumor Society, who was not involved in the Dana-Farber study, says even people with the same genetic mutations in their tumors might not respond similarly to the same treatment.

She also says tumor samples may not always be representative of the entire tumor. For example, a genetic mutation might be found in some cells of the tumor but not in others. That could affect what drugs patients are prescribed.

The study didn’t track the outcome of the patients after their treatments. One of the uncertainties of precision medicine is whether these genomic tests lead to any improvements in life expectancy or quality of life for patients.

Want to go ad free? No ad blockers needed.

Become an Insider
Already an Insider? Log in.
Genomic testing of pediatric brain tumor samples may help guide diagnosis and treatment.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

    Bimonthly digital/PDF edition

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special interest publications

    Discount to MIT Technology Review events

    Special discounts to select partner offerings

    Ad-free web experience

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.